Exposition domiciliaire aux moisissures : quel impact sur le statut aspergillaire du patient atteint de mucoviscidose ?

National audienc

Treatment of toxoplasmosis: Current options and future perspectives

Toxoplasmosis is a worldwide parasitic disease infecting about one third of humans, with possible severe outcomes in neonates and immunocompromised patients. Despite continuous and successful efforts to improve diagnosis, therapeutic schemes have barely evolved since many years. This article aims at reviewing the main clinical trials and current treatment practices, and at addressing future perspectives in the light of ongoing researches

Mise au point et actualités sur la leishmaniose viscérale méditerranéenne [Changing patterns of disease and treatment of mediterranean visceral leishmaniasis]

National audienc

A case report of photodermatoses induced by the antifungal drug terbinafine

International audienc

Aléa de la marche pieds nus en zone tropicale

International audienc

Détection d’Aspergillus dans le liquide bronchiolo-alvéolaire pour le diagnostic de l’aspergillose invasive : comparaison des performances de 2 méthodes PCR

National audienc

Anaphylaxis due to anisakidosis

International audienc

A 37-Year-Old Woman With Left Sensomotor Seizure

International audienc

Pneumocystose chez les patients immunodéprimés non infectés par le VIH [Pneumocystosis in non-HIV-infected immunocompromised patients]

National audiencePneumocystis jiroveci (formerly P. carinii) is an opportunistic fungus responsible for pneumonia in immunocompromised patients. Pneumocystosis in non-HIV-infected patients differs from AIDS-associated pneumocystosis in mostly two aspects: diagnosis is more difficult, and prognosis is worse. Hence, efforts should be made to target immunocompromised patients at higher risk of pneumocystosis, so that they are prescribed long-term, low-dose, trimethoprime-sulfamethoxazole, highly effective for pneumocystosis prophylaxis. Patients at highest risk include those with medium and small vessels vasculitis, lymphoproliferative B disorders (chronic or acute lymphocytic leukaemia, non-Hodgkin lymphoma), and solid cancer on long-term corticosteroids. Conversely, widespread use of prophylaxis in all patients carrier of inflammatory diseases on long-term corticosteroids is not warranted. The management of pneumocystosis in non-AIDS immunocompromised patients follows the rules established for AIDS patients. The diagnosis relies on the detection of P. jiroveci cyst on respiratory samples, while PCR does not reliably discriminate infection from colonization, in 2015. High-doses trimethoprim-sulfamethoxazole is, by far, the treatment of choice. The benefit of adjuvant corticosteroid therapy for hypoxic patients, well documented in AIDS patients, has a much lower level of evidence in non-HIV-infected patients, most of them being already on corticosteroid by the time of pneumocystosis diagnosis anyway. However, based on its striking impact on morbi-mortality in AIDS patients, adjuvant corticosteroid is recommended in hypoxic, non-HIV-infected patients with pneumocystosis by many experts and scientific societies

Analyse physicochimique et microbiologique de la Qualité de l’Air Intérieur dans les établissements HOSPitaliers : l’étude QAIHOSP

National audienc